Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

NCT03463460 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Thymic Carcinoma

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab
DRUG: Sunitinib Malate

Sponsor

Dwight Owen

Collaborators

[object Object]